drugset / Trial / NCT01039961

PK Study of IV Formulation of GW856553

NCT01039961

Phase 1 Completed 16 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety of an IV infusion of GW856553 in healthy volunteers.

Timeline

Start
2010-02-02
Primary completion
2010-04-15
Completion
2010-04-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Losmapimod Small molecule 1 mg Intravenous
Subject Losmapimod Small molecule 15 mg Intravenous